vs

Side-by-side financial comparison of APOGEE ENTERPRISES, INC. (APOG) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

APOGEE ENTERPRISES, INC. is the larger business by last-quarter revenue ($351.4M vs $267.3M, roughly 1.3× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 1.6%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 2.9%).

Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

APOG vs ASND — Head-to-Head

Bigger by revenue
APOG
APOG
1.3× larger
APOG
$351.4M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+40.7% gap
ASND
42.3%
1.6%
APOG
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
2.9%
APOG

Income Statement — Q4 FY2026 vs Q4 FY2025

Metric
APOG
APOG
ASND
ASND
Revenue
$351.4M
$267.3M
Net Profit
$16.6M
Gross Margin
22.4%
90.5%
Operating Margin
7.3%
Net Margin
4.7%
Revenue YoY
1.6%
42.3%
Net Profit YoY
568.8%
EPS (diluted)
$0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APOG
APOG
ASND
ASND
Q1 26
$351.4M
Q4 25
$348.6M
$267.3M
Q3 25
$358.2M
$230.7M
Q2 25
$346.6M
$170.7M
Q1 25
$345.7M
$109.0M
Q4 24
$341.3M
$187.8M
Q3 24
$342.4M
$62.5M
Q2 24
$331.5M
$38.9M
Net Profit
APOG
APOG
ASND
ASND
Q1 26
$16.6M
Q4 25
$16.5M
Q3 25
$23.6M
$-65.9M
Q2 25
$-2.7M
$-42.0M
Q1 25
$2.5M
$-102.2M
Q4 24
$21.0M
Q3 24
$30.6M
$-107.1M
Q2 24
$31.0M
$-118.1M
Gross Margin
APOG
APOG
ASND
ASND
Q1 26
22.4%
Q4 25
23.8%
90.5%
Q3 25
23.1%
89.5%
Q2 25
21.7%
80.1%
Q1 25
21.6%
82.6%
Q4 24
26.1%
91.9%
Q3 24
28.4%
80.6%
Q2 24
29.8%
68.2%
Operating Margin
APOG
APOG
ASND
ASND
Q1 26
7.3%
Q4 25
7.1%
Q3 25
7.5%
5.1%
Q2 25
2.0%
-33.5%
Q1 25
1.8%
-103.2%
Q4 24
8.4%
Q3 24
12.3%
-167.3%
Q2 24
12.5%
-370.2%
Net Margin
APOG
APOG
ASND
ASND
Q1 26
4.7%
Q4 25
4.7%
Q3 25
6.6%
-28.5%
Q2 25
-0.8%
-24.6%
Q1 25
0.7%
-93.7%
Q4 24
6.1%
Q3 24
8.9%
-171.5%
Q2 24
9.4%
-303.9%
EPS (diluted)
APOG
APOG
ASND
ASND
Q1 26
$0.78
Q4 25
$0.77
Q3 25
$1.10
Q2 25
$-0.13
Q1 25
$0.12
Q4 24
$0.96
Q3 24
$1.40
Q2 24
$1.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APOG
APOG
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$39.5M
$665.3M
Total DebtLower is stronger
$232.3M
Stockholders' EquityBook value
$511.8M
$-175.8M
Total Assets
$1.1B
$1.4B
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APOG
APOG
ASND
ASND
Q1 26
$39.5M
Q4 25
$41.3M
$665.3M
Q3 25
$39.5M
$582.2M
Q2 25
$32.8M
$533.6M
Q1 25
$41.4M
$559.4M
Q4 24
$43.9M
$604.3M
Q3 24
$51.0M
$675.6M
Q2 24
$30.4M
$279.4M
Total Debt
APOG
APOG
ASND
ASND
Q1 26
$232.3M
Q4 25
Q3 25
Q2 25
Q1 25
$285.0M
Q4 24
Q3 24
Q2 24
Stockholders' Equity
APOG
APOG
ASND
ASND
Q1 26
$511.8M
Q4 25
$512.3M
$-175.8M
Q3 25
$500.2M
$-188.0M
Q2 25
$481.8M
$-202.6M
Q1 25
$487.9M
$-205.0M
Q4 24
$522.1M
$-114.2M
Q3 24
$506.4M
$-105.1M
Q2 24
$480.0M
$-346.8M
Total Assets
APOG
APOG
ASND
ASND
Q1 26
$1.1B
Q4 25
$1.1B
$1.4B
Q3 25
$1.2B
$1.2B
Q2 25
$1.2B
$1.2B
Q1 25
$1.2B
$1.1B
Q4 24
$1.2B
$1.3B
Q3 24
$917.1M
$1.2B
Q2 24
$889.0M
$819.0M
Debt / Equity
APOG
APOG
ASND
ASND
Q1 26
0.45×
Q4 25
Q3 25
Q2 25
Q1 25
0.58×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APOG
APOG
ASND
ASND
Operating Cash FlowLast quarter
$122.5M
$58.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
7.8%
Cash ConversionOCF / Net Profit
7.37×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APOG
APOG
ASND
ASND
Q1 26
$122.5M
Q4 25
$29.3M
$58.2M
Q3 25
$57.1M
Q2 25
$-19.8M
Q1 25
$30.0M
$-15.5M
Q4 24
$31.0M
$-330.7M
Q3 24
$58.7M
Q2 24
$5.5M
Free Cash Flow
APOG
APOG
ASND
ASND
Q1 26
Q4 25
$22.9M
Q3 25
$52.4M
Q2 25
$-26.9M
Q1 25
$19.1M
Q4 24
$22.0M
Q3 24
$50.2M
Q2 24
$-1.8M
FCF Margin
APOG
APOG
ASND
ASND
Q1 26
Q4 25
6.6%
Q3 25
14.6%
Q2 25
-7.8%
Q1 25
5.5%
Q4 24
6.4%
Q3 24
14.7%
Q2 24
-0.5%
Capex Intensity
APOG
APOG
ASND
ASND
Q1 26
7.8%
Q4 25
1.9%
Q3 25
1.3%
Q2 25
2.1%
Q1 25
3.2%
Q4 24
2.6%
Q3 24
2.5%
Q2 24
2.2%
Cash Conversion
APOG
APOG
ASND
ASND
Q1 26
7.37×
Q4 25
1.77×
Q3 25
2.41×
Q2 25
Q1 25
12.08×
Q4 24
1.48×
Q3 24
1.92×
Q2 24
0.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APOG
APOG

Architectural Services$127.1M36%
Architectural Metals$110.0M31%
Architectural Glass$67.4M19%
Performance Surfaces$54.3M15%

ASND
ASND

Segment breakdown not available.

Related Comparisons